Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery
Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiatio...
Saved in:
Published in | Journal of clinical and diagnostic research Vol. 10; no. 7; pp. XC01 - XC04 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
India
JCDR Research and Publications (P) Limited
01.07.2016
JCDR Research and Publications Private Limited |
Subjects | |
Online Access | Get full text |
ISSN | 2249-782X 0973-709X |
DOI | 10.7860/JCDR/2016/18181.8126 |
Cover
Abstract | Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear.
The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy.
Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method.
The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly.
We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion. |
---|---|
AbstractList | Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear.INTRODUCTIONCisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear.The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy.AIMThe aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy.Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method.MATERIALS AND METHODSTwo cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method.The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly.RESULTSThe highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly.We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.CONCLUSIONWe conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion. Introduction: Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear. Aim: The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy. Materials and Methods: Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method. Results: The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly. Conclusion: We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion. Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear. The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy. Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method. The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly. We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion. |
Author | Rajkumar, Pradeep |
AuthorAffiliation | 3 Associate Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India 4 Associate Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India 1 Fellow, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India 5 Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India 6 Assistant Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India 7 Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India 2 Professor, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India |
AuthorAffiliation_xml | – name: 6 Assistant Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India – name: 1 Fellow, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India – name: 7 Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India – name: 3 Associate Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India – name: 5 Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India – name: 4 Associate Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India – name: 2 Professor, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India |
Author_xml | – sequence: 1 givenname: Pradeep surname: Rajkumar fullname: Rajkumar, Pradeep |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27630935$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Uk1vGyEQRVWqxkn7D6qKYy-O-YbNoVJlp4krS5HSVMoNsSxrE63Bhd1I-ffFXqdqeqg4ADPvvYGZdwZOQgwOgI8YXUgl0Oz7fHE3IwiLGVZlXShMxBswQZWkU4mqhxMwIYRVU6nIwyk4y_kRISEEFe_AKZGCooryCRjmPu860_sA5zFYF_pULjFkWCKrGNbQhAb-2MTUw8Uw5uAytEMuh0u43O46b4-MNibYbxy83fV-azp477cOxhbemcaPxIXr_JNLz-_B29Z02X047ufg57er-_nNdHV7vZx_XU0tk6yfEkbaqqotds5yYrEiAgnjGmWdI0whLGmFHBfUcCIwa2tLcSN5XTtTOyENPQfLUbeJ5lHvUnlWetbReH0IxLTWJvXedk4jJClXymDGaiapqRQiSkmu6qbmiMqi9WXU2g311jVjq7pXoq8zwW_0Oj5pjsqUKlYEPh8FUvw1uNzrrc_WdZ0JLg5Zl-8hXgnCSYF--rvWnyIvcyuAyxFgU8w5uVZb3x96XEr7TmOk9ybRe5PovUn0wSR6b5JCZv-QX_T_S_sNuDTBEQ |
CitedBy_id | crossref_primary_10_7554_eLife_56235 crossref_primary_10_1080_10937404_2021_1884921 crossref_primary_10_1172_jci_insight_171140 crossref_primary_10_3389_fonc_2021_750677 crossref_primary_10_3389_fphar_2022_879748 crossref_primary_10_1021_acs_chemrestox_6b00389 crossref_primary_10_26599_NBE_2023_9290008 crossref_primary_10_1021_acs_jmedchem_4c02373 crossref_primary_10_1186_s12885_017_3864_6 crossref_primary_10_14814_phy2_14927 crossref_primary_10_3389_fonc_2023_1212604 |
ContentType | Journal Article |
Copyright | 2016 Journal of Clinical and Diagnostic Research 2016 |
Copyright_xml | – notice: 2016 Journal of Clinical and Diagnostic Research 2016 |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.7860/JCDR/2016/18181.8126 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ (Directory of Open Access Journals) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 0973-709X |
EndPage | XC04 |
ExternalDocumentID | oai_doaj_org_article_0073588a144b473a980288758bdb5037 PMC5020194 27630935 10_7860_JCDR_2016_18181_8126 |
Genre | Journal Article |
GroupedDBID | --- 2WC 5VS AAYXX ABDBF ACUHS ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV CITATION DIK E3Z EBD EOJEC ESX GROUPED_DOAJ GX1 HYE KQ8 M~E OBODZ OK1 P6G RNS RPM TR2 TUS ~8M NPM 7X8 5PM |
ID | FETCH-LOGICAL-c474t-242f99bc1eec52c182606aed8cee248017390e563a52614fbc31d75bbeabe67a3 |
IEDL.DBID | DOA |
ISSN | 2249-782X |
IngestDate | Wed Aug 27 01:31:17 EDT 2025 Thu Aug 21 18:43:14 EDT 2025 Thu Jul 10 17:36:10 EDT 2025 Thu Jan 02 22:26:27 EST 2025 Tue Jul 01 01:23:23 EDT 2025 Thu Apr 24 23:10:31 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | Radiosensitizing Chemotherapy Radiation therapy |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c474t-242f99bc1eec52c182606aed8cee248017390e563a52614fbc31d75bbeabe67a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/0073588a144b473a980288758bdb5037 |
PMID | 27630935 |
PQID | 1820596252 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_0073588a144b473a980288758bdb5037 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5020194 proquest_miscellaneous_1820596252 pubmed_primary_27630935 crossref_citationtrail_10_7860_JCDR_2016_18181_8126 crossref_primary_10_7860_JCDR_2016_18181_8126 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-07-01 |
PublicationDateYYYYMMDD | 2016-07-01 |
PublicationDate_xml | – month: 07 year: 2016 text: 2016-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | India |
PublicationPlace_xml | – name: India – name: Delhi, India |
PublicationTitle | Journal of clinical and diagnostic research |
PublicationTitleAlternate | J Clin Diagn Res |
PublicationYear | 2016 |
Publisher | JCDR Research and Publications (P) Limited JCDR Research and Publications Private Limited |
Publisher_xml | – name: JCDR Research and Publications (P) Limited – name: JCDR Research and Publications Private Limited |
References | 21621941 - J Pharm Biomed Anal. 2011 Aug 25;56(1):126-30 2254110 - Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1183-9 8573645 - J Pharm Biomed Anal. 1995 Aug;13(9):1173-8 8003553 - J Pharm Biomed Anal. 1994 Feb;12(2):265-71 2364368 - Cancer. 1990 Aug 1;66(3):564-9 14645636 - N Engl J Med. 2003 Nov 27;349(22):2091-8 12899503 - Acta Oncol. 2003;42(4):315-25 9614438 - Jpn J Clin Oncol. 1998 Mar;28(3):168-75 15151521 - Br J Clin Pharmacol. 2004 Jun;57(6):756-63 25793192 - Biomed Res Int. 2015;2015:307576 2824080 - Cancer Chemother Pharmacol. 1987;20(3):211-2 16181764 - J Pharm Biomed Anal. 2006 Mar 3;40(4):833-9 9466668 - Int J Cancer. 1998 Feb 9;75(4):635-42 2045298 - Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1235-41 3943271 - Clin Pharmacol Ther. 1986 Feb;39(2):136-44 16861770 - Phys Med Biol. 2006 Aug 7;51(15):3625-37 15068570 - J Anal Toxicol. 2004 Mar;28(2):138-40 |
References_xml | – reference: 21621941 - J Pharm Biomed Anal. 2011 Aug 25;56(1):126-30 – reference: 9614438 - Jpn J Clin Oncol. 1998 Mar;28(3):168-75 – reference: 16861770 - Phys Med Biol. 2006 Aug 7;51(15):3625-37 – reference: 15151521 - Br J Clin Pharmacol. 2004 Jun;57(6):756-63 – reference: 8003553 - J Pharm Biomed Anal. 1994 Feb;12(2):265-71 – reference: 3943271 - Clin Pharmacol Ther. 1986 Feb;39(2):136-44 – reference: 2045298 - Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1235-41 – reference: 12899503 - Acta Oncol. 2003;42(4):315-25 – reference: 16181764 - J Pharm Biomed Anal. 2006 Mar 3;40(4):833-9 – reference: 14645636 - N Engl J Med. 2003 Nov 27;349(22):2091-8 – reference: 25793192 - Biomed Res Int. 2015;2015:307576 – reference: 2364368 - Cancer. 1990 Aug 1;66(3):564-9 – reference: 2254110 - Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1183-9 – reference: 15068570 - J Anal Toxicol. 2004 Mar;28(2):138-40 – reference: 8573645 - J Pharm Biomed Anal. 1995 Aug;13(9):1173-8 – reference: 9466668 - Int J Cancer. 1998 Feb 9;75(4):635-42 – reference: 2824080 - Cancer Chemother Pharmacol. 1987;20(3):211-2 |
SSID | ssj0066636 |
Score | 2.2562218 |
Snippet | Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge... Introduction: Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | XC01 |
SubjectTerms | chemotherapy Oncology Section radiation therapy radiosensitizing |
Title | Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27630935 https://www.proquest.com/docview/1820596252 https://pubmed.ncbi.nlm.nih.gov/PMC5020194 https://doaj.org/article/0073588a144b473a980288758bdb5037 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDxUXBJRCeFSuxDVsEsexzQ12-1RbpJZKe7Nsx6GVirdiNwf-PTN2drVbIfXSyx7yUCzP2N83O-NvCPmsOIBu4ZpcOgYBSmVsLo2DhadaIByu6lhs33Z-0Rxf16dTPl1r9YU1YUkeOE3cCFNJXEoDxN_WghklARGBZEvbWl6weI68UMUymEp7MHDy2BwQ8EnlgIHTdGhOyKYYnY4nlxDyl80IwE2WXwDhmg1Qitr9_yOcD-sm14Do8CV5MTBI-i2N_BV55sNrsn0-5Mh3SD--nd9jhVugYzyTGAZh3DmFK2ez8Iua0NKrG-DddNKne_QkdD3-b_aVnqyVmFNgtBQYIv0BG8tv-CgeGKGzjl6iokF8ceLvsLLj7xtyfXjwc3ycD80VcleLeoGp4E4p60rvHa8chhlFY3wrATUr1JQRTBWeN8xwCLLqzoItW8Gt9cb6Rhi2S7bCLPh3hCpeC8dQ971DdTDg7LbufCeAaxgDFCgjbDm72g3K49gA405DBII20WgTjTbR0SYabZKRfPXWfVLeeOT572i41bOomx0vgDfpwZv0Y96Ukf2l2TWsM0yemOBn_Vyj0D12KuJVRt4mN1h9qoJNGhPKGREbDrIxls074fYmanlzoOulqt8_xeA_kOc4J6mY-CPZWvzp_SegTAu7F1cH_B5Ny38nvQ5j |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cisplatin+Concentrations+in+Long+and+Short+Duration+Infusion%3A+Implications+for+the+Optimal+Time+of+Radiation+Delivery&rft.jtitle=Journal+of+clinical+and+diagnostic+research&rft.au=Pradeep+Rajkumar&rft.au=Binu+Susan+Mathew&rft.au=Saikat+Das&rft.au=Rajesh+Isaiah&rft.date=2016-07-01&rft.pub=JCDR+Research+and+Publications+Private+Limited&rft.issn=2249-782X&rft.eissn=0973-709X&rft.volume=10&rft.issue=7&rft.spage=XC01&rft.epage=XC04&rft_id=info:doi/10.7860%2FJCDR%2F2016%2F18181.8126&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_0073588a144b473a980288758bdb5037 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2249-782X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2249-782X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2249-782X&client=summon |